Hypertension is the leading modifiable cause of premature death and hence one of the
global targets of World Health Organization for prevention. Hypertension also affects the …

The discovery and development of so-called gut hormone co-agonists as a new class of
drugs for the treatment of diabetes and obesity is considered a transformative breakthrough …

Background Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …

Abstract Type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease
(CKD), are recognized among the most disruptive public health issues of the current century …

Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …

Background Tirzepatide, a once-weekly glucose-dependent insulinotropic
polypeptide/glucagon-like peptide-1 receptor agonist, is approved in the United States …

Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the
dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged
place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic …

OBJECTIVE Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated
glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine) …

Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease (CKD),
leading end-stage renal disease. Thus, DKD is one of the most important diabetic …